Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG
dc.contributor.author | Jalili, A. | |
dc.contributor.author | Calzavara-Pinton, P. | |
dc.contributor.author | Kircik, L. | |
dc.contributor.author | Lons-Danic, D. | |
dc.contributor.author | Pink, A. | |
dc.contributor.author | Tyring, S. | |
dc.contributor.author | de la Cueva, P. | |
dc.contributor.author | Gooderham, M. | |
dc.contributor.author | Segaert, S. | |
dc.contributor.author | Nyholm, N. | |
dc.contributor.author | Thoning, H. | |
dc.contributor.author | Petersen, B. | |
dc.contributor.author | Thaçi, D. | |
dc.contributor.department | Dermatology, School of Medicine | |
dc.date.accessioned | 2023-08-02T10:03:58Z | |
dc.date.available | 2023-08-02T10:03:58Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Background: Psoriasis has important physical and psychosocial effects that extend beyond the skin. Understanding the impact of treatment on health-related quality of life (HRQoL) and patient-perceived symptom severity in psoriasis is key to clinical decision-making. Objectives: This post hoc analysis of the PSO-LONG trial data assessed the impact of long-term proactive or reactive management with fixed-dose combination calcipotriene 50 µg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) foam on patient-reported outcomes (PROs) in patients with psoriasis vulgaris. Methods: Five hundred and twenty-one patients from the Phase 3, randomized, double-blind PSO-LONG trial were included. An initial 4-week, open-label phase of fixed-dose combination Cal/BD foam once daily (QD) was followed by a 52-week maintenance phase, at the start of which patients were randomized to a proactive management arm (Cal/BD foam twice weekly) or reactive management arm (vehicle foam twice weekly). Patient-perceived symptom severity and HRQoL were assessed using the Psoriasis Symptom Inventory (PSI), the Dermatology Life Quality Index (DLQI) and the EuroQol-5D for psoriasis (EQ-5D-5L-PSO). Results: Statistically and clinically significant improvements were observed across all PRO measures. The mean difference (standard deviation) from baseline to Week 4 was -8.97 (6.18) for PSI, -6.02 (5.46) for DLQI and 0.11 (0.15) for EQ-5D-5L-PSO scores. During maintenance, patients receiving reactive management had significantly higher DLQI (15% [p = 0.007]) and PSI (15% [p = 0.0128]) and a numerically lower EQ-5D-5L-PSO mean area under the curve score than patients receiving proactive management (1% [p = 0.0842]). Conclusions: Cal/BD foam significantly improved DLQI, EQ-5D-5L-PSO and PSI scores during the open-label and maintenance phases. Patients assigned to proactive management had significantly better DLQI and PSI scores and numerically better EQ-5D-5L-PSO versus reactive management. Additionally, baseline flare was associated with worse PROs than the start of a relapse, and patients starting a relapse also had worse PROs than patients in remission. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Jalili A, Calzavara-Pinton P, Kircik L, et al. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG. J Eur Acad Dermatol Venereol. 2022;36(1):60-67. doi:10.1111/jdv.17673 | |
dc.identifier.uri | https://hdl.handle.net/1805/34668 | |
dc.language.iso | en_US | |
dc.publisher | Wiley | |
dc.relation.isversionof | 10.1111/jdv.17673 | |
dc.relation.journal | Journal of the European Academy of Dermatology and Venereology | |
dc.rights | Attribution-NonCommercial 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.source | PMC | |
dc.subject | Betamethasone dipropionate | |
dc.subject | Calcipotriol | |
dc.subject | Psoriasis | |
dc.subject | Topical administration | |
dc.title | Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG | |
dc.type | Article |